JP2025508867A5 - - Google Patents

Info

Publication number
JP2025508867A5
JP2025508867A5 JP2024550555A JP2024550555A JP2025508867A5 JP 2025508867 A5 JP2025508867 A5 JP 2025508867A5 JP 2024550555 A JP2024550555 A JP 2024550555A JP 2024550555 A JP2024550555 A JP 2024550555A JP 2025508867 A5 JP2025508867 A5 JP 2025508867A5
Authority
JP
Japan
Prior art keywords
seq
sequence number
cdrl1
cdrl2
cdrl3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024550555A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508867A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/054762 external-priority patent/WO2023161457A1/en
Publication of JP2025508867A publication Critical patent/JP2025508867A/ja
Publication of JP2025508867A5 publication Critical patent/JP2025508867A5/ja
Pending legal-status Critical Current

Links

JP2024550555A 2022-02-27 2023-02-26 Cd277と腫瘍抗原に対する二重特異性抗体 Pending JP2025508867A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP22159045 2022-02-27
EP22159045 2022-02-27
EP22162761 2022-03-17
EP22162761 2022-03-17
EP23157433 2023-02-19
EP23157433 2023-02-19
PCT/EP2023/054762 WO2023161457A1 (en) 2022-02-27 2023-02-26 Bispecific antibodies against cd277 and a tumor-antigen

Publications (2)

Publication Number Publication Date
JP2025508867A JP2025508867A (ja) 2025-04-10
JP2025508867A5 true JP2025508867A5 (cg-RX-API-DMAC7.html) 2026-03-04

Family

ID=85382872

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024550555A Pending JP2025508867A (ja) 2022-02-27 2023-02-26 Cd277と腫瘍抗原に対する二重特異性抗体

Country Status (9)

Country Link
US (1) US20250163157A1 (cg-RX-API-DMAC7.html)
EP (1) EP4482859A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025508867A (cg-RX-API-DMAC7.html)
KR (1) KR20240149438A (cg-RX-API-DMAC7.html)
CN (1) CN119173528A (cg-RX-API-DMAC7.html)
CA (1) CA3243624A1 (cg-RX-API-DMAC7.html)
IL (1) IL314678A (cg-RX-API-DMAC7.html)
MX (1) MX2024010485A (cg-RX-API-DMAC7.html)
WO (1) WO2023161457A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025532758A (ja) 2022-10-04 2025-10-03 イムチェック セラピューティクス エスエーエス 癌の治療における使用のためのbtn3a活性化抗体、bcl2阻害剤及び低メチル化剤の併用
JP2026506893A (ja) 2023-02-23 2026-02-27 イムチェック セラピューティクス エスエーエス Btn3a活性化抗体と免役チェックポイント阻害剤の併用
TW202506731A (zh) 2023-04-27 2025-02-16 法商感應檢查療法公司 治療多重抗藥性細菌感染之方法
WO2024261239A1 (en) 2023-06-23 2024-12-26 Imcheck Therapeutics Bispecific antibodies targeting btn3a and the pd-1/pd-l1 inhibitory axis

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
PT2845866T (pt) 2006-10-27 2017-08-09 Genentech Inc Anticorpos e imunoconjugados e utilizações dos mesmos
EP1997832A1 (en) 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
US20120064096A1 (en) 2009-03-17 2012-03-15 Universite De La Mediterranee BTLA Antibodies and Uses Thereof
BRPI1014089A2 (pt) 2009-04-02 2016-04-19 Roche Glycart Ag anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples
CA2769473A1 (en) 2009-07-31 2011-02-03 N.V. Organon Fully human antibodies to btla
WO2012080769A1 (en) 2010-12-15 2012-06-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd277 antibodies and uses thereof
US20150353643A1 (en) 2013-09-24 2015-12-10 Universite De La Mediterranee - Aix-Marseille Ii Anti-cd277 antibodies and uses thereof
WO2012119077A1 (en) 2011-03-02 2012-09-07 Morphotek Inc. Co -administration of eribulin and farletuzumab for the treatment of breast cancer
WO2013174403A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
EP4177273A1 (en) 2013-02-20 2023-05-10 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014165818A2 (en) 2013-04-05 2014-10-09 T Cell Therapeutics, Inc. Compositions and methods for preventing and treating prostate cancer
RS61010B1 (sr) 2014-11-20 2020-11-30 Hoffmann La Roche Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3
WO2017055388A2 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific t cell activating antigen binding molecules
CA3013333A1 (en) 2016-02-26 2017-08-31 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies having specificity for btla and uses thereof
KR102491752B1 (ko) 2016-08-29 2023-01-26 싸이오서스 테라퓨틱스 엘티디. 이중특이성 T 세포 세포 관여자(BiTE)가 보강된 아데노바이러스
EP3773676A4 (en) 2018-04-03 2022-05-18 Dragonfly Therapeutics, Inc. PROTEINS THAT BIND NKG2D, CD16 AND AN ANTIGEN ASSOCIATED WITH TUMORS, MDSCS AND/OR TAMS
WO2019211370A1 (en) 2018-05-03 2019-11-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
PL3830119T3 (pl) 2018-08-01 2026-05-25 Imcheck Therapeutics Przeciwciała anty-btn3a i ich zastosowanie w leczeniu nowotworów albo zaburzeń zakaźnych
JP7457007B2 (ja) 2018-09-19 2024-03-27 ラヴァ・セラピューティクス・エヌ・ヴイ 二重作用CD1d免疫グロブリン
US12441789B2 (en) 2019-07-11 2025-10-14 Memorial Sloan Kettering Cancer Center DLL3-targeting antibodies and uses thereof
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
AR122656A1 (es) 2020-06-19 2022-09-28 Hoffmann La Roche Anticuerpos que se unen a cd3 / folr1

Similar Documents

Publication Publication Date Title
JP2021534096A5 (cg-RX-API-DMAC7.html)
JP2018108081A5 (cg-RX-API-DMAC7.html)
JP2022548783A5 (cg-RX-API-DMAC7.html)
HRP20240626T1 (hr) Bispecifična antitijela protiv ceacam5 i cd3
JP2021533159A5 (cg-RX-API-DMAC7.html)
JP2024541680A5 (cg-RX-API-DMAC7.html)
JP2006512899A5 (cg-RX-API-DMAC7.html)
JP2017529838A5 (cg-RX-API-DMAC7.html)
JP2024542194A5 (cg-RX-API-DMAC7.html)
JP2014158469A5 (cg-RX-API-DMAC7.html)
JP2022540083A5 (cg-RX-API-DMAC7.html)
JP2025032102A5 (cg-RX-API-DMAC7.html)
JP2011207882A5 (cg-RX-API-DMAC7.html)
TW201026325A (en) Fibroblast growth factor receptor-3 (FGFR-3) inhibitors and methods of treatment
JP2024016024A5 (cg-RX-API-DMAC7.html)
JP2020500834A5 (cg-RX-API-DMAC7.html)
JP2025128343A5 (cg-RX-API-DMAC7.html)
JP2025092589A5 (cg-RX-API-DMAC7.html)
JP2024109911A5 (cg-RX-API-DMAC7.html)
JP2022545741A5 (cg-RX-API-DMAC7.html)
JP2022507253A5 (cg-RX-API-DMAC7.html)
JP2017535257A5 (cg-RX-API-DMAC7.html)
JP2025038088A5 (cg-RX-API-DMAC7.html)
JP2024504390A5 (cg-RX-API-DMAC7.html)
JP2023518153A5 (cg-RX-API-DMAC7.html)